MENU
+Compare
BEAM
Stock ticker: NASDAQ
AS OF
Sep 12 closing price
Price
$20.60
Change
-$0.95 (-4.41%)
Capitalization
2.08B

BEAM Beam Therapeutics Forecast, Technical & Fundamental Analysis

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases... Show more

BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BEAM with price predictions
Sep 12, 2025

BEAM's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for BEAM moved out of overbought territory on September 12, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BEAM broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BEAM entered a downward trend on September 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 03, 2025. You may want to consider a long position or call options on BEAM as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on August 28, 2025. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

BEAM moved above its 50-day moving average on September 05, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on September 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.991) is normal, around the industry mean (20.731). P/E Ratio (0.000) is within average values for comparable stocks, (53.474). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.171). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (30.395) is also within normal values, averaging (337.655).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BEAM is expected to report earnings to rise 3.00% to -102 cents per share on November 10

Beam Therapeutics BEAM Stock Earnings Reports
Q3'25
Est.
$-1.03
Q2'25
Beat
by $0.11
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.18
Q3'24
Beat
by $0.01
The last earnings report on August 05 showed earnings per share of -100 cents, beating the estimate of -111 cents. With 2.44M shares outstanding, the current market capitalization sits at 2.08B.
A.I. Advisor
published General Information

General Information

a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
238 Main Street
Phone
+1 857 327-8775
Employees
436
Web
https://www.beamtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AGLOX15.340.03
+0.20%
Ariel Global Investor
EIEAX38.99-0.18
-0.46%
Eaton Vance Tax-Managed Eq Aset Allc I
FBLEX14.79-0.08
-0.54%
Fidelity Series Stk Selec Lg Cp Val
AMCGX11.42-0.09
-0.78%
Alger Mid Cap Growth B
BREFX42.10-0.44
-1.03%
Baron Real Estate Retail

BEAM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-4.41%
CRSP - BEAM
66%
Closely correlated
+0.66%
NTLA - BEAM
63%
Loosely correlated
N/A
RXRX - BEAM
61%
Loosely correlated
-0.41%
AXON - BEAM
57%
Loosely correlated
+0.67%
SYRE - BEAM
57%
Loosely correlated
-3.40%
More

Groups containing BEAM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-4.41%
BEAM
(2 stocks)
86%
Closely correlated
-1.87%